PharmPK Discussion - Clonazepam PK

• On 15 Dec 2012 at 18:26:34, Matt Lehrer (m.lehrer.-at-.centurylink.net) sent the message
  

  
  Any suggestions regarding resources discussing the pharmacokinetics of
  Clonazepam.  For exapmle, when does the plasma level peak and at what
  level ng/ml?  What are the therepeutic and toxic ranges?  How about a
  single dose of 4mg versus a steady state?  The manufacturer itself
  (Roche) seems to equivocate on these issues in it's own literature.
  
  

  Back to the Top

• On 16 Dec 2012 at 13:52:44, William Wolowich (wwolowic.-a-.nova.edu) sent the message
  

  
  [I've made a small start on an eBook version of the PharmPK archives, =
  iBook and pdf format. Comments, suggestions welcome. Probably more work =
  than worth. Let me know. Last two entries on my eBooks page, =
  http;//www.pharmpk.com/MyeBooks.html - db]
  
  The following message was posted to: PharmPK
  
  from Goodman and Gilmans appendix: (an excellent starting point for PK
  info)
  
  Metabolized by CYP3A. Range of Cmax values following a single 2-mg IV
  dose (model-fitted for bolus dose) or mean following a 2-mg oral dose
  (tablet) given to healthy adults. Most patients, including children
  whose seizures are controlled by clonazepam have steady-state =
  concentrations
  of 5-70 ng/mL. However, patients who do not respond and those with side
  effects achieve similar levels.
  
  Reference: Berlin A, et al. Pharmacokinetics of the anticonvulsant drug
  clonazepam evaluated
  from single oral and intravenous doses and by repeated oral
  administration. Eur J Clin
  Pharmacol, 1975, 9:155-159.
  
  

  Back to the Top

• On 17 Dec 2012 at 11:46:03, David Bourne (david.at.boomer.org) sent the message
  

  
  Dear Mr Matt Lehrer,
  
  Please find below the Public Assessment Reports and Scientific Articles
  which will answer your queries regarding Clonazepam.
  
  1. MHRA's Public Assessment Report, Decentralized Procedure, Clonazepam,
  UK/H/1890/01-02/DC, UK License no. PL 20620/0045-6, NRIM Limited.
  
  =
  http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con09115=
  7.pdf
  
  2. MHRA's Public Assessment Report, Decentralized Procedure, Clonazepam,
  UK/H/2487/001-02/DC, UK License no. PL 00427/0157-8, Rosemont
  Pharmaceuticals Limited.
  
  =
  http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con14359=
  2.pdf
  3. Crevoisier C, Delisle MC, Joseph I, Foletti G.Comparative single-dose
  pharmacokinetics of clonazepam following intravenous, intramuscular and
  oral administration to healthy volunteers.=20
  Eur Neurol. 2003;49(3):173-7.
  
  4. BL Chauhan, SP Sane, SN Revankar, L Rammamurthy, B Doshi, AD Bhatt,
  VR Bhate, RD Kulkarni, Comparative Bioavailability Study of Clonazepam
  After Oral Administration of Two Tablet Formulations.=20
  =
  http://www.japi.org/october2000/s-Comparative%20Bioavailability%20Study%20=
  of%20Clonazepam%20After%20Oral%20Administration%20of%20Two%20Tablet%20Form=
  ulations.htm
  
  5. MedSafe Datasheet, Paxam (Clonazepam 0.5 mg and 2.0 mg tablets)
  http://www.medsafe.govt.nz/profs/datasheet/p/Paxamtab.pdf
  
  Regards,
  Dr.S.Gunasakaran, MD
  Head - Clinical Research & Medical Affairs,
  Azidus Clinical Research Organization, India
  Global Moderator - ClinicalResearchForum
  www.clinicalresearchsociety.org
  
  

  Back to the Top

Copyright 1995-2011 David W. A. Bourne (david@boomer.org)